FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

CNBC Published Updated Stocks
Sign in to save

Why it matters

The FDA chief has expressed concerns that the US is falling behind China in early drug development, citing three key bottlenecks in the approval process.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bearish Confidence 80% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bearish sentiment with 80% confidence.

Evidence trail

Evidence
Source CNBC
Claim FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
AI inference Bearish · 80%
Generated 2026-02-18 20:35

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
47292

Original source

Makary pointed to three bottlenecks: hospital contracting, ethical reviews and approvals and the Investigational New Drug applications process

Read the full article on CNBC

Original article published by CNBC on February 18, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage